HOUSTON, June 11, 2019 /PRNewswire/ -- Soliton, Inc.,
(Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device
company with a novel and proprietary platform technology licensed
from The University of Texas on behalf
of the MD Anderson Cancer Center ("MD Anderson"), will conduct a
webcast to discuss its recent announcements regarding its
significant discovery of acoustic subcision and its 510(k)
clearance for its acoustic shockwave RAP device. The webcast will
be at 4:30 p.m. ET on Tuesday, June
11, 2019.
Webcast Details
Interested parties can access the live webcast on the Company's
website under the Investors section at http://ir.soliton.com.
A replay of the webcast call will be available for 30 days at
https://ir.soliton.com.
Join our more than 200K fans here
to follow the Company: https://soly-investors.com
About Soliton, Inc.
Soliton, Inc. is a medical device company with a novel and
proprietary platform technology licensed from MD Anderson. The
Company's first FDA cleared commercial product uses rapid pulses of
acoustic shockwaves as an accessory to lasers for the removal of
unwanted tattoos. The Company is based in Houston, Texas, and is actively engaged in
bringing its Rapid Acoustic Pulse ("RAP") device to the market. The
Company believes this "Soliton" method has the potential to lower
tattoo removal costs for patients, while increasing profitability
to practitioners, compared to current laser removal
methods. Soliton is also investigating additional indications
for its RAP technology based on early clinical testing indicating
the potential for RAP to reduce the appearance of cellulite and the
potential to assist existing fat reduction technologies in the
reduction of subcutaneous fat, as well as preclinical testing
suggesting the potential for additional indications related to
abberant fibrotic activity. Although our device is now cleared
for sale in the United States for
the tattoo removal indication, it remains investigational and not
yet cleared for these additional indications.
For more information about the Company, please
visit: http://www.soliton.com
Forward-Looking Statements
Some of the statements in this release are forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995, which involve
risks and uncertainties. These statements relate to future
events, future expectations, plans and prospects. Although Soliton
believes that the expectations reflected in such forward-looking
statements are reasonable as of the date made, expectations may
prove to have been materially different from the results expressed
or implied by such forward-looking statements. Soliton has
attempted to identify forward-looking statements by terminology
including ''believes,'' ''estimates,'' ''anticipates,''
''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,''
''may,'' ''could,'' ''might,'' ''will,'' ''should,''
''approximately'' or other words that convey uncertainty of future
events or outcomes to identify these forward-looking statements.
These statements are only predictions and involve known and unknown
risks, uncertainties, and other factors, including those discussed
under in our SEC filings, including under the heading "Item 1A.
Risk Factors" in the Form 10-K for year ended December 31, 2018 we filed with the SEC and
updated from time to time in our Form 10-Q filings and in our other
public filings with the SEC. Any forward-looking statements
contained in this release speak only as of its date. Soliton
undertakes no obligation to update any forward-looking statements
contained in this release to reflect events or circumstances
occurring after its date or to reflect the occurrence of
unanticipated events.
View original
content:http://www.prnewswire.com/news-releases/soliton-confirms-conference-call-to-discuss-recently-announced-significant-discovery-and-fda-clearance-for-today-at-430-pm-et-300865144.html
SOURCE Soliton, Inc.